Eric Verdin

Dr. Verdin is the President and CEO of the Buck Institute for Research on aging and a Professor of Medicine at the University of California, San Francisco. He studies molecular metabolism and its effect on human aging and associated diseases, such as Alzheimer’s. Alongside his doctorate and research at the University of Liege and Harvard Medical School, he has published more than 400 academic papers, holds 15 patents, and stands among the top 1% of the most-cited scientists.

A Glenn Award winner and member of several scientific organizations, such as the American Association for the American Society for Clinical Investigation and the Association of American Physicians, Dr. Verdin has also served at advanced biotech companies. Namely – Acylin, Elixir, Calico (Google), Nokia, Sofinnova Ventures, Pfizer, J&J, etc.